Beranda › Leukemia Limfoblastik Akut › New Mexico › Albuquerque
Uji klinis Leukemia Limfoblastik Akut di Albuquerque, NM
3 studi untuk Leukemia Limfoblastik Akut mencari peserta di lokasi sekitar Albuquerque (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- dan 1 lainnya
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- University of New Mexico Cancer Center, Albuquerque
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Menerima pesertaStudi observasional
- University of New Mexico Cancer Center, Albuquerque
Uji klinis Leukemia Limfoblastik Akut di kota lain
- Houston, TX28 studi
- New York City, NY24 studi
- Baldwin Park, CA21 studi
- Seattle, WA21 studi
- Chicago, IL19 studi
- Atlanta, GA19 studi
- Memphis, TN16 studi
- Philadelphia, PA16 studi
- Washington, DC16 studi
- Boston, MA15 studi
- Los Angeles, CA14 studi
- Durham, NC13 studi
Studi lain di Albuquerque
- Kanker Paru Non-Sel Kecil18 studi
- Kanker Payudara17 studi
- Kanker Ovarium15 studi
- Kanker Paru14 studi
- Kanker (semua jenis)14 studi
- Kanker Endometrium12 studi
- Kanker Metastatik12 studi
- Diabetes Tipe 211 studi
- Penyakit Kardiovaskular10 studi
- Kanker Prostat9 studi
- Melanoma9 studi
- Leukemia Mieloid Akut9 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.